Antidepressant Drugs
... cerebellum and limbic areas (hippocampus, amygdala, hypothalamus, thalamus). Mood: -- higher functions performed by the cortex. Cognitive function: -- function of cortex. Drive and motivation: -- function of brainstem Memory and emotion: -- function of the hippocampus and amygdala. ...
... cerebellum and limbic areas (hippocampus, amygdala, hypothalamus, thalamus). Mood: -- higher functions performed by the cortex. Cognitive function: -- function of cortex. Drive and motivation: -- function of brainstem Memory and emotion: -- function of the hippocampus and amygdala. ...
Hx - Palliative Care
... methylphenidate acts as a dopamine and norepinephrine reuptake inhibitor resulting in a prolongation of dopamine (D1/D2) receptor effects. It is believed that methylphenidate activates the brain stem arousal system and cortex. ...
... methylphenidate acts as a dopamine and norepinephrine reuptake inhibitor resulting in a prolongation of dopamine (D1/D2) receptor effects. It is believed that methylphenidate activates the brain stem arousal system and cortex. ...
Antiemetic drugs
... Antiemetic mechanism • Neurokinin 1 (NK1) receptor antagonist on nucleus of tractus solitaries and Visceral afferent nerves • So it prevent both peripheral and central stimulation of the vomiting center Uses as antiemetic: • In combination with 5-HT3 blockers to treat vomiting due to cancer chemothe ...
... Antiemetic mechanism • Neurokinin 1 (NK1) receptor antagonist on nucleus of tractus solitaries and Visceral afferent nerves • So it prevent both peripheral and central stimulation of the vomiting center Uses as antiemetic: • In combination with 5-HT3 blockers to treat vomiting due to cancer chemothe ...
Depression and anxiety Lou haiyan（娄海燕）
... Anxiety Anxiety is an unpleasant emotional experience characterized by fear disproportionate to the severity of stressful factors in the environment, or fear without cause. ...
... Anxiety Anxiety is an unpleasant emotional experience characterized by fear disproportionate to the severity of stressful factors in the environment, or fear without cause. ...
Zofran (Ondansetron)
... • Do not remove med from blister pack until just prior to dosing • Do not try and push tablet through the foil • Peel blister backing completely off packet • Gently remove tablet from packet • Place on patients tongue to dissolve and be swallowed with saliva ...
... • Do not remove med from blister pack until just prior to dosing • Do not try and push tablet through the foil • Peel blister backing completely off packet • Gently remove tablet from packet • Place on patients tongue to dissolve and be swallowed with saliva ...
Adrenoceptor Antagonists
... • It is highly selective for α1 receptors and typically 1000-fold less potent at α2 receptors. • Thus, it produces less tachycardia than phentolamine and phenoxybenzamine ...
... • It is highly selective for α1 receptors and typically 1000-fold less potent at α2 receptors. • Thus, it produces less tachycardia than phentolamine and phenoxybenzamine ...
Pharmacology/Therapeutics II Block I Lectures
... H+/K+ ATPase. Prodrugs – activated in acid environment – enter the parietal cells from the blood The prolonged duration of anti-secretory action of PPI reflects irreversible inactivation by covalent modification, of the parietal cell H+ ,K+ -ATPase, rather than a prolonged serum half-life. A single ...
... H+/K+ ATPase. Prodrugs – activated in acid environment – enter the parietal cells from the blood The prolonged duration of anti-secretory action of PPI reflects irreversible inactivation by covalent modification, of the parietal cell H+ ,K+ -ATPase, rather than a prolonged serum half-life. A single ...
Sympatholytics
... By blocking the alpha1-receptors associated with venous smooth muscle, prazosin-like drugs, inhibit the sympathetically mediated vasoconstriction associated with postural changes. Hence, orthostatic hypotension can occur. Drugs like clonidine cause orthostasis due to its CNS actions that block the s ...
... By blocking the alpha1-receptors associated with venous smooth muscle, prazosin-like drugs, inhibit the sympathetically mediated vasoconstriction associated with postural changes. Hence, orthostatic hypotension can occur. Drugs like clonidine cause orthostasis due to its CNS actions that block the s ...
351 Pharmacology 3rd sf
... The extent to which the ligand/drug is capable of binding and remained bound to receptor. High Affinity – the ligand binds well and remains bound long enough to activate the receptor. Low Affinity – the ligand binds less well and may not remain bound long enough to activate the receptor. ...
... The extent to which the ligand/drug is capable of binding and remained bound to receptor. High Affinity – the ligand binds well and remains bound long enough to activate the receptor. Low Affinity – the ligand binds less well and may not remain bound long enough to activate the receptor. ...
Darifenacin Hydrobromide
... activity and M3 receptor selectivity better, Nmonosubstituted, N, Ndisubstituted or ester is anticholinergic activity decreases even without anticholinergic activity. ...
... activity and M3 receptor selectivity better, Nmonosubstituted, N, Ndisubstituted or ester is anticholinergic activity decreases even without anticholinergic activity. ...
Cell to cell communication, homeostasis and control pathways
... research investigates variation in membrane protein transporters and receptors. Amino acid variants, for example, can change the rate of transport, the rate of ATP cleavage, and specificity (affinity) characteristics, to name just a few. Go to the Pharmocogenetics Knowledge Base at www.pharmgkb.org ...
... research investigates variation in membrane protein transporters and receptors. Amino acid variants, for example, can change the rate of transport, the rate of ATP cleavage, and specificity (affinity) characteristics, to name just a few. Go to the Pharmocogenetics Knowledge Base at www.pharmgkb.org ...
a homogenous flow cytometric method for the combined
... receptors (GPCRs) requires the determination of both affinity and activity. The combination of binding assay and functional test using the same measurement setup would considerably facilitate the process of drug evaluation. As part of a project to develop fluorescence-based methods for the investiga ...
... receptors (GPCRs) requires the determination of both affinity and activity. The combination of binding assay and functional test using the same measurement setup would considerably facilitate the process of drug evaluation. As part of a project to develop fluorescence-based methods for the investiga ...
DIABETIC ENTEROPATHY: TWO DIFFICULT PROBLEMS
... Metaclopramide p Is it worth a trial of metaclopramide in moderate to severe Gastroparesis? ...
... Metaclopramide p Is it worth a trial of metaclopramide in moderate to severe Gastroparesis? ...
Lexapro Information
... 4. Stereochemical designations: s/r-mirror images; d/l-rotate a plane of polarized light in opposite directions. 5. As most receptors can distinguish between stereoisomers, they can have different biologic activity. Examples include R-carvone vs. S-carvone(spearmint, caraway), Darvon vs. Novrad, and ...
... 4. Stereochemical designations: s/r-mirror images; d/l-rotate a plane of polarized light in opposite directions. 5. As most receptors can distinguish between stereoisomers, they can have different biologic activity. Examples include R-carvone vs. S-carvone(spearmint, caraway), Darvon vs. Novrad, and ...
21 Schnell Kytril - Lebanese Society of Medical Oncology
... 1. Orr, Chen. Am J Physiol Gastrointest Liver Physiol 2002;283:G1226–31 2. http://www.geriatricsyllabus.com/syllabus/main.jsp?cid=SCC-DER-4-2 3. Wilkinson, de Picciotto. S Afr J Commun Disord 1999;46:55–64 4. Lebovits et al. Cancer 1990;65:17–22; 5. Schroder et al. J Neural Transm Suppl 1998;54:51–9 ...
... 1. Orr, Chen. Am J Physiol Gastrointest Liver Physiol 2002;283:G1226–31 2. http://www.geriatricsyllabus.com/syllabus/main.jsp?cid=SCC-DER-4-2 3. Wilkinson, de Picciotto. S Afr J Commun Disord 1999;46:55–64 4. Lebovits et al. Cancer 1990;65:17–22; 5. Schroder et al. J Neural Transm Suppl 1998;54:51–9 ...
Pharmacology II - 4-12
... a. Increased neurotransmitter release b.NMDA receptor antagonism c. Serotonin receptor agonist d.Opioid receptor agonist ...
... a. Increased neurotransmitter release b.NMDA receptor antagonism c. Serotonin receptor agonist d.Opioid receptor agonist ...
felix may 2nd year neuroscience Neuroreceptor characterisation by
... even just absorbed in the filter paper. Subtracting the lowest value for QNB binding yields the ‘specific’ binding of QNB. These figures can be considered the inverse binding of atropine - that is because if a receptor is not occupied by one, it will be by the other. Binding of atropine to muscarini ...
... even just absorbed in the filter paper. Subtracting the lowest value for QNB binding yields the ‘specific’ binding of QNB. These figures can be considered the inverse binding of atropine - that is because if a receptor is not occupied by one, it will be by the other. Binding of atropine to muscarini ...
PSYC550 Psychopharmacology
... – Medication to treat a disease – A chemical that is likely to be abused – An “exogenous” chemical that significantly alters the function of certain bodily cells when taken in relatively low doses (chemical is not required for normal cellular functioning) ...
... – Medication to treat a disease – A chemical that is likely to be abused – An “exogenous” chemical that significantly alters the function of certain bodily cells when taken in relatively low doses (chemical is not required for normal cellular functioning) ...
Feng Na - USD Biology
... Two-bottle choice phase: access to alcohol and water in Richter tubes for ...
... Two-bottle choice phase: access to alcohol and water in Richter tubes for ...
07 Adrenoceptor-antagonist
... migraine, cirrhosis with varices, and congestive heart failure), it should not be assumed that all members of this class of drugs are interchangeable; the appropriate drug should be selected from those that have documented efficacy for the disease • For example in heart failure clinical trials have ...
... migraine, cirrhosis with varices, and congestive heart failure), it should not be assumed that all members of this class of drugs are interchangeable; the appropriate drug should be selected from those that have documented efficacy for the disease • For example in heart failure clinical trials have ...
5-HT2a – receptor agonist
... (nausea, vomiting, dizziness, anxiety, headache, hallucinations and irrational behavior, myosis) • MDMA-like chemical structure + weak inhibitor MAO • extremely long time before peak (4-7 hours), effects last for 24-72 hours ...
... (nausea, vomiting, dizziness, anxiety, headache, hallucinations and irrational behavior, myosis) • MDMA-like chemical structure + weak inhibitor MAO • extremely long time before peak (4-7 hours), effects last for 24-72 hours ...
Evidence for the Existence of Nonmonotonic Dose
... • Examples are well accepted for both therapeutic and toxic actions of natural and synthetic compounds • “Non-monotonic” curves do not violate fundamental understanding of receptor mediated actions • All complex biological systems do violate the assumptions necessary for receptor occupancy theory to ...
... • Examples are well accepted for both therapeutic and toxic actions of natural and synthetic compounds • “Non-monotonic” curves do not violate fundamental understanding of receptor mediated actions • All complex biological systems do violate the assumptions necessary for receptor occupancy theory to ...
5-HT3 antagonist
The 5-HT3 antagonists, informally known as ""setrons"", are a class of drugs that act as receptor antagonists at the 5-HT3 receptor, a subtype of serotonin receptor found in terminals of the vagus nerve and in certain areas of the brain.With the notable exception of alosetron and cilansetron, which are used in the treatment of irritable bowel syndrome, all 5-HT3 antagonists are antiemetics, used in the prevention and treatment of nausea and vomiting. They are particularly effective in controlling the nausea and vomiting produced by cancer chemotherapy and are considered the gold standard for this purpose.The 5-HT3 antagonists may be identified by the suffix –setron, and are classified under code A04AA of the WHO's Anatomical Therapeutic Chemical Classification System.